Clinical trials: Desmoid Fibromatosis
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
Soft Tissue Sarcoma, Desmoid Tumors
HIFU Ablation of Soft Tissue Sarcoma
Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years.
- Trial name
- SarcAblate (NCT05111964)
- Testing
- High Intensity Focused Ultrasound Ablation, Tumour Biopsy and Venous Blood Tests
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Oxford University Hospitals NHS Trust
Familial Adenomatous Polyposis (FAP)
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps.
- Trial name
- FAP (NCT07729371)
- Testing
- ST316 IV
- Volunteers
- 40 people
- Sponsor
- Sapience Therapeutics
Fibromatosis
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Aggressive fibromatosis (AF, also known as desmoid tumor) is a fibroproliferative neoplasm that typically arises in the abdomen but can develop at other anatomic sites, most commonly in the extremities.
- Trial name
- NCT02495519
- Testing
- Imatinib
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Yonsei University
Desmoid Tumor, Desmoid-type Fibromatosis
Quality of Life of Patients With Desmoid-type Fibromatosis
Rationale: Desmoid-type fibromatosis (DTF) is a rare, histologically benign, soft tissue tumour. Although incapable of metastasizing, the clinical course is unpredictable and can be aggressive because of local invasive growth.
- Trial name
- QUALIFIED (NCT04289077)
- Testing
- Questionnaires
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Erasmus Medical Center
Desmoid Tumor
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
Phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
- Trial name
- NCT03459469
- Testing
- Tegavivint
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Iterion Therapeutics
Desmoid Tumors, Aggressive Fibromatosis
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Background: Desmoid tumors (also known as aggressive fibromatosis), are rare, locally invasive, slow-growing soft-tissue tumors.
- Trial name
- NCT01981551
- Testing
- PF-03084014
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Dermoid
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
- Trial name
- MP-VAC-206 (NCT06219733)
- Testing
- Vactosertib, Imatinib
- Where
- South Korea
- Sponsor
- MedPacto, Inc.
Desmoid Tumors
Cryoablation for Advanced and Refractory Desmoid Tumors
Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population.
- Trial name
- CARDT (NCT06113094)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Desmoid Tumors, Fibromatosis
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
The purpose of this study is to examine the response rate of desmoid tumors to hydroxyurea. The investigators hypothesize that hydroxyurea will be a safe, non-toxic alternative to aggressive surgery or chemotherapy for this…
- Trial name
- NCT00978146
- Testing
- Hydroxyurea
- Sponsor
- Children's Hospital of Philadelphia
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Advanced Desmoid Tumor, Advanced Chondrosarcoma
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform…
- Trial name
- Basket 1 (NCT00928525)
- Testing
- Imatinib Mesylate
- Where
- 7 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Italian Sarcoma Group
Desmoid Tumor, Quality of Life
Burden of Disease and Living Situation in Desmoid Patients
The main aim of the study is to assess the situation and quality of life of desmoid patients. Impaired areas of quality of life and the associated factors are to be identified.
- Trial name
- PROSa Desmoid (NCT06258421)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Technische Universität Dresden
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Desmoid Tumor
A Study in Adults With Desmoid Tumors
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics…
- Trial name
- NCT07541430
- Testing
- ES014
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Desmoid Tumor
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
"Wait \& see" is currently the standard of care of recently diagnosed desmoid tumors (DT). In case of progression or symptomatic disease, medical therapy is nowadays widely used including chemotherapy.
- Trial name
- CRYODESMO-02 (NCT06081400)
- Testing
- Cryoablation, Chemotherapy drug
- Where
- 13 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Strasbourg, France
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients who have aggressive fibromatoses.
- Trial name
- NCT00030680
- Testing
- radiation therapy
- Where
- 21 sites in Belgium, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret